If you are not redirected in five seconds, click here.

Updates in 

SYSTEMIC LUPUS ERYTHEMATOSUS

Unlocking Novel Paths to Patient Care

Program Description

Target Audience

This activity is intended for rheumatologists and other specialists involved in the management of patients with systemic lupus erythematosus (SLE).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe SLE pathophysiology with a focus on novel treatment targets
  • Evaluate patients with SLE using consensus classification criteria, measures of disease activity, and clinical trial endpoints
  • Discuss new clinical trial data and regulatory status for current and emerging targeted therapies in moderate-to-severe SLE
  • Manage patients with SLE based on a treat-to-target approach, evolving clinical evidence, unresolved symptoms, and patient preferences

Statement of Need

Despite improved understanding of pathophysiologic mechanisms, development of classification criteria, and hope for more available treatments, specialists face challenges in managing the diverse manifestations of SLE. This live CME webinar program will be offered 3 times, once for each US region – the eastern/Atlantic region, the central/Midwest region, and the western/Pacific region. National and regional experts in SLE will share interpretive insights on SLE diagnosis, SLE pathogenesis, traditional treatment modalities, and recent clinical trial data for newer targeted therapies. The program will also look at how clinicians and patients define treatment success and will feature several faculty discussions addressing today’s clinical challenges in SLE treatment. This forward-looking CME program will offer insights and evolving evidence to help rheumatologists provide care that minimizes recurrent disease activity flares and cumulative organ damage, both key factors in long-term outcomes.

Faculty

Richard A. Furie, MD

Chief, Division of Rheumatology
Chief, Division of Allergy and Immunology, Department of Medicine
Long Island Jewish Medical Center
Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Great Neck, New York

Roberto Caricchio, MD, FACR

Chief, Section of Rheumatology
Professor of Medicine and of Microbiology and Immunology
Director, Temple Lupus Program
Lewis Katz School of Medicine, Temple University
Philadelphia, Pennsylvania

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

PIM designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete an online evaluation form.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

CME Questions – PIM Contact Information

For information about the accreditation of this program, please contact PIM via e-mail at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information

For all other questions regarding this webinar series, please contact Christa Master at cmaster@integritasgrp.com.